Dmello, Crismita http://orcid.org/0000-0002-1688-9663
Zhao, Junfei
Chen, Li
Gould, Andrew
Castro, Brandyn
Arrieta, Victor A.
Zhang, Daniel Y. http://orcid.org/0000-0001-9962-9295
Kim, Kwang-Soo
Kanojia, Deepak
Zhang, Peng
Miska, Jason http://orcid.org/0000-0001-9608-2810
Yeeravalli, Ragini
Habashy, Karl
Saganty, Ruth
Kang, Seong Jae http://orcid.org/0000-0003-0982-3604
Fares, Jawad
Liu, Connor
Dunn, Gavin
Bartom, Elizabeth http://orcid.org/0000-0002-5618-2582
Schipma, Matthew J.
Hsu, Patrick D.
Alghamri, Mahmoud S.
Lesniak, Maciej S.
Heimberger, Amy B. http://orcid.org/0000-0002-9970-8695
Rabadan, Raul http://orcid.org/0000-0001-7946-9255
Lee-Chang, Catalina http://orcid.org/0000-0002-7675-2124
Sonabend, Adam M. http://orcid.org/0000-0002-8347-1945
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (1R01NS110703)
CU | National Cancer Institute, Cairo University (R01 CA120813, P50CA221747)
U.S. Department of Defense (W81XWH-20-1-0850)
Article History
Received: 22 December 2022
Accepted: 21 February 2023
First Online: 22 March 2023
Competing interests
: C.D., A.M.S., C.L-C, and L.C. are co-authors for the following patent filed by Northwestern University: Method of using checkpoint kinase 1/2 inhibitor therapy to modulate anti-tumoral response against cancer and sensitize gliomas to immunotherapy (US Patent App. 16/951,638). A.M.S. has received in-kind and or funding support for research from Agenus, BMS, and Carthera. R.R. is a member of the SAB of AimedBio, consultant for Arquimea Research and a founder of Genotwin. The remaining authors declare no other competing interests.